169 related articles for article (PubMed ID: 17583545)
21. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
[TBL] [Abstract][Full Text] [Related]
24. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
Fracasso PM; Burris H; Arquette MA; Govindan R; Gao F; Wright LP; Goodner SA; Greco FA; Jones SF; Willcut N; Chodkiewicz C; Pathak A; Springett GM; Simon GR; Sullivan DM; Marcelpoil R; Mayfield SD; Mauro D; Garrett CR
Clin Cancer Res; 2007 Feb; 13(3):986-93. PubMed ID: 17289894
[TBL] [Abstract][Full Text] [Related]
25. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Safran H; Charpentier KP; Kaubisch A; Mantripragada K; Dubel G; Perez K; Faricy-Anderson K; Miner T; Eng Y; Victor J; Plette A; Espat J; Bakalarski P; Wingate P; Berz D; Luppe D; Martel D; Rosati K; Aparo S
Am J Clin Oncol; 2015 Feb; 38(1):1-4. PubMed ID: 23648434
[TBL] [Abstract][Full Text] [Related]
27. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy.
Shao YY; Wu CH; Lu LC; Chan SY; Ma YY; Yen FC; Hsu CH; Cheng AL
J Hepatol; 2014 Feb; 60(2):313-8. PubMed ID: 24036008
[TBL] [Abstract][Full Text] [Related]
28. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
Koeberle D; Montemurro M; Samaras P; Majno P; Simcock M; Limacher A; Lerch S; Kovàcs K; Inauen R; Hess V; Saletti P; Borner M; Roth A; Bodoky G
Oncologist; 2010; 15(3):285-92. PubMed ID: 20203173
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients.
Hertlein L; Lenhard M; Kirschenhofer A; Kahlert S; Mayr D; Burges A; Friese K
Arch Gynecol Obstet; 2011 Jan; 283(1):109-13. PubMed ID: 20180130
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response.
Yeo W; Chan SL; Mo FK; Chu CM; Hui JW; Tong JH; Chan AW; Koh J; Hui EP; Loong H; Lee K; Li L; Ma B; To KF; Yu SC
BMC Cancer; 2015 May; 15():395. PubMed ID: 25962426
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
Wu J; Henderson C; Feun L; Van Veldhuizen P; Gold P; Zheng H; Ryan T; Blaszkowsky LS; Chen H; Costa M; Rosenzweig B; Nierodzik M; Hochster H; Muggia F; Abbadessa G; Lewis J; Zhu AX
Invest New Drugs; 2010 Oct; 28(5):670-6. PubMed ID: 19565187
[TBL] [Abstract][Full Text] [Related]
32. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
Knox JJ; Gill S; Synold TW; Biagi JJ; Major P; Feld R; Cripps C; Wainman N; Eisenhauer E; Seymour L
Invest New Drugs; 2008 Jun; 26(3):265-72. PubMed ID: 18196204
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Saltz LB; Meropol NJ; Loehrer PJ; Needle MN; Kopit J; Mayer RJ
J Clin Oncol; 2004 Apr; 22(7):1201-8. PubMed ID: 14993230
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.
Abou-Alfa GK; Capanu M; O'Reilly EM; Ma J; Chou JF; Gansukh B; Shia J; Kalin M; Katz S; Abad L; Reidy-Lagunes DL; Kelsen DP; Chen HX; Saltz LB
J Hepatol; 2014 Feb; 60(2):319-24. PubMed ID: 24045151
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
Locati LD; Bossi P; Perrone F; Potepan P; Crippa F; Mariani L; Casieri P; Orsenigo M; Losa M; Bergamini C; Liberatoscioli C; Quattrone P; Calderone RG; Rinaldi G; Pilotti S; Licitra L
Oral Oncol; 2009 Jul; 45(7):574-8. PubMed ID: 18804410
[TBL] [Abstract][Full Text] [Related]
36. Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).
Ramalingam SS; Lee JW; Belani CP; Aisner SC; Kolesar J; Howe C; Velasco MR; Schiller JH
J Clin Oncol; 2011 May; 29(13):1709-14. PubMed ID: 21422434
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series.
Montella L; Addeo R; Cennamo G; Vincenzi B; Palmieri R; Sperlongano P; Sperlongano R; Iodice P; Russo P; Del Prete S
Oncology; 2013; 84(5):265-72. PubMed ID: 23428832
[TBL] [Abstract][Full Text] [Related]
38. A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics.
Poojari R; Kini S; Srivastava R; Panda D
Mol Pharm; 2015 Nov; 12(11):3908-23. PubMed ID: 26426829
[TBL] [Abstract][Full Text] [Related]
39. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.
El Dika I; Lim HY; Yong WP; Lin CC; Yoon JH; Modiano M; Freilich B; Choi HJ; Chao TY; Kelley RK; Brown J; Knox J; Ryoo BY; Yau T; Abou-Alfa GK
Oncologist; 2019 Jun; 24(6):747-e218. PubMed ID: 30598500
[TBL] [Abstract][Full Text] [Related]
40. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.
Chan JA; Blaszkowsky LS; Enzinger PC; Ryan DP; Abrams TA; Zhu AX; Temel JS; Schrag D; Bhargava P; Meyerhardt JA; Wolpin BM; Fidias P; Zheng H; Florio S; Regan E; Fuchs CS
Ann Oncol; 2011 Jun; 22(6):1367-1373. PubMed ID: 21217058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
